Abstract
The mammalian dim-light photoreceptor rhodopsin is a prototypic G protein coupled receptor (GPCR), interacting with the G protein, transducin, rhodopsin kinase, and arrestin. All of these proteins interact with rhodopsin at its cytoplasmic surface. Structural and modeling studies have provided in-depth descriptions of the respective interfaces. Overlap and thus competition for binding surfaces is a major regulatory mechanism for signal processing. Recently, it was found that the same surface is also targeted by small molecules. These ligands can directly interfere with the binding and activation of the proteins of the signal transduction cascade, but they can also allosterically modulate the retinal ligand binding pocket. Because the pocket that is targeted contains residues that are highly conserved across Class A GPCRs, these findings imply that it may be possible to target multiple GPCRs with the same ligand(s). This is desirable for example in complex diseases such as cancer where multiple GPCRs participate in the disease networks.
Keywords: G protein coupled receptors, allostery, conformational changes, docking, protein-protein interactions, Rhodopsin, drug discovery, cytoplasm, GPCR, crystal structure
Current Drug Targets
Title: The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery
Volume: 13 Issue: 1
Author(s): Naveena Yanamala, Eric Gardner, Alec Riciutti and Judith Klein-Seetharaman
Affiliation:
Keywords: G protein coupled receptors, allostery, conformational changes, docking, protein-protein interactions, Rhodopsin, drug discovery, cytoplasm, GPCR, crystal structure
Abstract: The mammalian dim-light photoreceptor rhodopsin is a prototypic G protein coupled receptor (GPCR), interacting with the G protein, transducin, rhodopsin kinase, and arrestin. All of these proteins interact with rhodopsin at its cytoplasmic surface. Structural and modeling studies have provided in-depth descriptions of the respective interfaces. Overlap and thus competition for binding surfaces is a major regulatory mechanism for signal processing. Recently, it was found that the same surface is also targeted by small molecules. These ligands can directly interfere with the binding and activation of the proteins of the signal transduction cascade, but they can also allosterically modulate the retinal ligand binding pocket. Because the pocket that is targeted contains residues that are highly conserved across Class A GPCRs, these findings imply that it may be possible to target multiple GPCRs with the same ligand(s). This is desirable for example in complex diseases such as cancer where multiple GPCRs participate in the disease networks.
Export Options
About this article
Cite this article as:
Yanamala Naveena, Gardner Eric, Riciutti Alec and Klein-Seetharaman Judith, The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery, Current Drug Targets 2012; 13 (1) . https://dx.doi.org/10.2174/138945012798868461
DOI https://dx.doi.org/10.2174/138945012798868461 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules
Current Genomics Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry The Metabolomic Strategy in Tuberculosis Therapy
Combinatorial Chemistry & High Throughput Screening Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Expression and Function of PPARs in Cancer Stem Cells
Current Stem Cell Research & Therapy Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) The Medical Potential of Antimicrobial Peptides from Insects
Current Topics in Medicinal Chemistry The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease
Current Topics in Medicinal Chemistry A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Integrins as A New Target for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery